These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 8182932)

  • 1. In vitro susceptibility of acute leukemia cells to the cytotoxic activity of allogeneic and autologous lymphokine activated killer (LAK) effectors: correlation with the rate and duration of complete remission and with survival.
    Lauria F; Raspadori D; Rondelli D; Ventura MA; Foà R
    Leukemia; 1994 May; 8(5):724-8. PubMed ID: 8182932
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Susceptibility of human leukemia to allogeneic and autologous lymphokine-activated killer cell activity: analysis of 252 samples.
    Teichmann JV; Ludwig WD; Thiel E
    Nat Immun; 1992; 11(3):117-32. PubMed ID: 1392400
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Generation of LAK cells in vitro in patients with acute leukemia.
    Parrado A; Rodriguez-Fernandez JM; Casares S; Noguerol P; Plaza E; Parody R; Espigado I; de Blas JM; Garcia-Solis D
    Leukemia; 1993 Sep; 7(9):1344-8. PubMed ID: 8371585
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Defective lymphokine-activated killer cell generation and activity in acute leukemia patients with active disease.
    Foa R; Fierro MT; Cesano A; Guarini A; Bonferroni M; Raspadori D; Miniero R; Lauria F; Gavosto F
    Blood; 1991 Aug; 78(4):1041-6. PubMed ID: 1868239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inducibility of lymphokine activated killer (LAK) cells in patients with acute myelogenous leukaemia in complete remission and its clinical relevance.
    Archimbaud E; Bailly M; Doré JF
    Br J Haematol; 1991 Mar; 77(3):328-34. PubMed ID: 2012757
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Susceptibility of adult acute lymphoblastic leukemia blasts to lysis by lymphokine-activated killer cells.
    Archimbaud E; Thomas X; Campos L; Magaud JP; Fiere D; Doré JF
    Leukemia; 1991 Nov; 5(11):967-71. PubMed ID: 1961038
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Susceptibility of acute myelogenous leukemia blasts to lysis by lymphokine-activated killer (LAK) cells and its clinical relevance.
    Archimbaud E; Thomas X; Campos L; Fiere D; Doré JF
    Leuk Res; 1992; 16(6-7):673-80. PubMed ID: 1378919
    [TBL] [Abstract][Full Text] [Related]  

  • 8. VLA-6 (CDw49f) is an important adhesion molecule in NK cell-mediated cytotoxicity following autologous or allogeneic bone marrow transplantation.
    Lowdell MW; Shamim F; Hamon M; Macdonald ID; Prentice HG
    Exp Hematol; 1995 Dec; 23(14):1530-4. PubMed ID: 8542943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Autologous bone marrow transplantation followed by interleukin-2 in children with advanced leukemia: a pilot study.
    Meloni G; Foà R; Tosti S; Vignetti M; Mancini F; Guarini A; Marchis D; Gavosto F; Mandelli F
    Leukemia; 1992 Aug; 6(8):780-5. PubMed ID: 1640729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro and in vivo susceptibility of human leukemic cells to lymphokine activated killer activity.
    Fierro MT; Liao XS; Lusso P; Bonferroni M; Matera L; Cesano A; Lista P; Arione R; Forni G; Foa R
    Leukemia; 1988 Jan; 2(1):50-4. PubMed ID: 3257539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lymphokine-activated killer cytotoxicity against leukaemic blast cells.
    Tratkiewicz JA; Szer J; Boyd RL
    Clin Exp Immunol; 1990 Apr; 80(1):94-9. PubMed ID: 2323104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased susceptibility to lymphokine activated killer (LAK) lysis of relapsing vs. newly diagnosed acute leukemic cells without changes in drug resistance or in the expression of adhesion molecules.
    Arienti F; Gambacorti-Passerini C; Borin L; Rivoltini L; Orazi A; Pogliani EM; Corneo G; Parmiani G
    Ann Oncol; 1992 Feb; 3(2):155-62. PubMed ID: 1606087
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Heterogeneity of lymphokine-activated killer cells induced by IL-2. Separate lymphoid subpopulations lyse tumor, allogeneic blasts, and modified syngeneic blasts.
    LeFor AT; Eisenthal A; Rosenberg SA
    J Immunol; 1988 Jun; 140(11):4062-9. PubMed ID: 3259603
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cytokines alter target cell susceptibility to lysis: I. Evaluation of non-major histocompatibility complex-restricted effectors reveals differential effects on natural and lymphokine-activated killing.
    Wiebke EA; Custer MC; Rosenberg SA; Lotze MT
    J Biol Response Mod; 1990 Apr; 9(2):113-26. PubMed ID: 2111373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expansion of natural killer cells with lytic activity against autologous blasts from adult and pediatric acute lymphoid leukemia patients in complete hematologic remission.
    Torelli GF; Guarini A; Maggio R; Alfieri C; Vitale A; Foà R
    Haematologica; 2005 Jun; 90(6):785-92. PubMed ID: 15951291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro resistance of the brown Norway rat acute myelocytic leukemia (BNML) to lymphokine-activated killer activity.
    Gaiser JF; Kloosterman TC; Martens AC; Hagenbeek A
    Leukemia; 1993 May; 7(5):736-41. PubMed ID: 8483327
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acute myeloblastic leukaemia: graft-versus-host and graft-versus-leukaemia responses to autologous IL-2 activated lymphocytes in rapid and slow disease.
    Boughton BJ; Simpson AW
    Cytokines Cell Mol Ther; 1999 Mar; 5(1):1-6. PubMed ID: 10390074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of human interleukin 3 on the susceptibility of fresh leukemia cells to interleukin-2-induced lymphokine activated killing activity.
    Cesano A; Lista P; Bellone G; Geuna M; Brizzi MF; Rossi PR; Pegoraro L; Oberholtzer E; Matera L
    Leukemia; 1992 Jun; 6(6):567-73. PubMed ID: 1376379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interleukin-2 induction of lymphokine-activated killer activity in the peripheral blood of an acute lymphoblastic leukaemia patient--case study.
    Dickinson AM; Lennard AL; Cartner R; Proctor SJ
    Leukemia; 1992 Sep; 6(9):957-60. PubMed ID: 1518307
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GM-CSF-mediated proliferation induction improves the susceptibility of leukemia cells to lymphokine-activated killer cells.
    Teichmann JV; Ludwig WD; Thiel E
    Int J Hematol; 1992 Jun; 55(3):255-64. PubMed ID: 1498316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.